Kiniksa Pharmaceuticals InternationalKNSA
Recorded

Kiniksa Pharmaceuticals International Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Roger SongSenior Biotech Analyst

All right. Welcome everyone to 2026 Jefferies Global Healthcare Conference in London. My name is Roger Song, Senior Analyst covering biotech in the U.S. It is my pleasure to have a fireside chat with our next company, Kiniksa. We have a full crew here. We have Sanj Patel, CEO, Ross Moat, President and COO, and John Paolini, CMO. Welcome, gentlemen. Thank you. Excellent.

Roger SongSenior Biotech Analyst

Before we dive in, a lot of different topics, it is very good momentum for entire Kiniksa. Maybe, Sanj, can you give us a state of the union about Kiniksa, and why you are excited about the future, particularly for 2027?

Sanj PatelCEO

Yeah. Thank you, Roger, and thanks to Jefferies also for hosting us today. Before I get started, please note we will be making forward-looking statements today that are subject to risks and uncertainties. A review of those statements, risk factors can be found in our SEC filings. Roger, yes, a lot to be excited about actually at Kiniksa Pharmaceuticals right now. We are obviously a very growth-orientated company. We have got our lead commercial product, ARCALYST, now, which is about five-plus years on the market since launch, and that is doing incredibly well, but still an awful lot more growth we feel that we can have with ARCALYST, and really leading and expanding our leadership position in the IL-1 alpha and beta inhibition franchise. So that is what we are very excited about.

Sanj PatelCEO

Beyond ARCALYST, we have a thriving pipeline, actually now in our phase III pivotal study with KPL-387, which is a monthly IL-1 alpha and beta inhibitor. We will have readout from our phase III study in the second half of next year, so that is really very exciting, and that is actually a monthly liquid formulation with the potential for an auto-injector. ARCALYST is a weekly injection. Beyond that, we have KPL-1161, which is a potentially quarterly IL-1 alpha and beta inhibition molecule. A lot to be excited about. We will actually be in the clinic with KPL-1161 later this year. Obviously, commercially, we are very much focused on continuing that growth within ARCALYST, but also excited about bringing KPL-387 and KPL-1161 closer to the market. A lot to do. Excellent.

Roger SongSenior Biotech Analyst

Thanks, Sanj. You do have a very successful commercial franchise, ARCALYST. Maybe we will start with that. We saw the 3Q earning you just reported. It is pretty good Q-on-Q growth, and also the penetration continue to grow. Can you just give us the breakdown, what drove that, in the instance of new patient or the longer duration, compliance, and maybe some pricing difference, gross-to-net? Can you give us some breakdown, the driver for the growth?

Sanj PatelCEO

Yeah, great. I mean, maybe I will give you an overview, and then Ross can jump in with some specific numbers. Essentially, most of the growth has been around new patient enrollments on the commercial side. Certainly, duration continues, as I think we last reported, said it is around three years on therapy. Very much a chronic disorder, if you like, and chronic treatment. But it has been around patient enrollments. You have mentioned compliance, that continues to be strong. Payer approval is very strong. Those continue to build. Obviously, it is not easy. As with any rare disease, it is all about execution and continuing to educate physicians, get our data out there. We obviously had a very successful pivotal study with RHAPSODY for ARCALYST, and that was very important. On top of that, our registry data continues to support long-term treatment.

Sanj PatelCEO

We are really focused on now increasing the number of multiple prescribers, new prescribers, and I think Ross will talk about how we have done that over the recent months and years.

Ross MoatPresident and COO

Yeah. Yeah. Thanks, Sanj and Roger.

Ross MoatPresident and COO

Certainly all the things that you mentioned, Sanj. We see that the commercial fundamentals continue to be very strong, whether that is compliance rate, patient acceptability of therapy, satisfaction on therapy, the payer approval rates, all remain very strong across the board for ARCALYST. But particularly with the new patient enrollments.

Ross MoatPresident and COO

Yeah. Ultimately what is driving that is satisfaction with treatment when physicians know how to prescribe the drug and continue to prescribe the drug for their next patients.

Ross MoatPresident and COO

It really has that halo effect. Ultimately, we have seen a substantial increase in the number of physicians that are prescribing ARCALYST for recurrent pericarditis. If you look at the breadth of prescribing, we grew in the last quarter by around 450 physicians, new physicians that have not prescribed ARCALYST launch to date, who now are. Repeat prescribers, we have got about 30% of our total prescribing pool that have now prescribed for two or more patients. That grew pretty substantially in the last quarter. Ultimately, our focus is really on the long term and the opportunity that we have ahead with recurrent pericarditis and with ARCALYST supporting these patients.

Ross MoatPresident and COO

If you look at the number of physicians that are looking after these patients, to think about the opportunity ahead, we have got around 5,450 unique prescribers who have prescribed ARCALYST launch to date. But that is out of a total pool of between 25,000 and 30,000 physicians who see a recurrent pericarditis patient in any given year. Clearly, the opportunity for us to keep going on from here for the months, years, quarters, years ahead is pretty substantial. That is for the breadth and the depth.

Ross MoatPresident and COO

If you think that we have got around 30% of our prescribing base that have prescribed for two or more patients, again, clearly that is showing that there is very substantial opportunity for us to continue to work on in the years ahead to make sure that we address more and more patients that are suffering from ultimately what is a very debilitating disease, and ARCALYST is the only approved therapy for recurrent pericarditis.

Roger SongSenior Biotech Analyst

Excellent. Then, since the growth is mostly driven by the new patient, do you know the breakdown between the new patient versus the continuous repeat patient at this moment in your business?

Ross MoatPresident and COO

Yeah. So, it is a pretty healthy split, almost a 50/50 split. It is just over 50% of all new enrollments coming in a given quarter that are from repeat prescribers, and obviously the other portion being new prescribers. Going off the figures that I just shared around the totality of how many physicians are out there looking after these patients, clearly there is substantial opportunity. But the fact that just over 50% are coming from repeat prescribers, I think, tells you that both the whole strategy around the depth and the breadth of potential prescribing is a huge opportunity for us.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day